As mentioned above, SGLT2 inhibitors have brought new hope for improving the prognosis of DKD and CKD.3, –5 Developed as drugs that promote urinary glucose excretion and lower blood glucose levels, SGLT2 inhibitors were initially expected to improve glomerular hyperfiltration, reducing proteinuria and, therefore, improving renal outcome. Here, SLC5A2 is linked to chronic kidney disease.